The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
See JNCCN.org for supplemental online content.
HeinleinCAChangC. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol2002;16:2181–2187.
HugginsCHodgesCV. Studies on prostatic cancer: I. The effect of castration, of estrogen and androgen injection on serum phsphatases in metastatic carcinoma of prostate. Cancer Res1941;1:293–297.
TitusMASchellMJLihFB. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res2005;11:4653–4657.
MohlerJLTitusMABaiS. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res2011;71:1486–1496.
ChangKHLiRPapari-ZareeiM. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A2011;108:13728–13733.
TitusMAGregoryCWFordOHIII. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res2005;11:4365–4371.
HelpapBEgevadL. The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. Virchows Arch2006;449:622–627.
WiltonJHTitusMAEfstathiouE. Androgenic biomarker profiling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry. Prostate2014;74:722–731.
Guidance for Industry: Bioanalytical Method Validation. Available at: http://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf. Accessed july 26 2016.
GregoryCWHamilKGKimD. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res1998;58:5718–5724.
MohlerJLMorrisTLFordOHIII. Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. Prostate2002;51:247–255.
KimDGregoryCWFrenchFS. Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft. Am J Pathol2002;160:219–226.
StahlFSchnorrDPilzC. Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer, heart diseases and under surgery stress. Exp Clin Endocrinol1992;99:68–70.
KimWZhangLWiltonJH. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res2014;20:6269–6276.
GitonFTrabadoSMaioneL. Sex steroids, precursors, and metabolite deficiencies in men with isolated hypogonadotropic hypogonadism and panhypopituitarism: a GCMS-based comparative study. J Clin Endocrinol Metab2015;100:E292–296.
KraanGPDullaartRPPrattJJ. The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. J Clin Endocrinol Metab1998;83:1247–1252.
MohlerJLGastonKEMooreDT. Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J Urol2004;171(6 Pt 1):2277–2280.
AraiSShibataYNakamuraY. Development of prostate cancer in a patient with primary hypogonadism: intratumoural steroidogenesis in prostate cancer tissues. Andrology2013;1:169–174.
WilsonJDRoehrbornC. Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts. J Clin Endocrinol Metab1999;84:4324–4331.
McNelisJCManolopoulosKNGathercoleLL. Dehydroepiandrosterone exerts antiglucocorticoid action on human preadipocyte proliferation, differentiation, and glucose uptake. Am J Physiol Endocrinol Metab2013;305:E1134–1144.
SaccoMValentiGCorvi MoraP. DHEA, a selective glucocorticoid receptor antagonist: its role in immune system regulation and metabolism. J Endocrinol Invest2002;25(10 Suppl):81–82.
OlssonMEkstromLGuillemetteC. Correlation between circulatory, local prostatic, and intra-prostatic androgen levels. Prostate2011;71:909–914.
OesterlingJEEpsteinJIWalshPC. The inability of adrenal androgens to stimulate the adult human prostate: an autopsy evaluation of men with hypogonadotropic hypogonadism and panhypopituitarism. J Urol1986;136:1030–1034.